Results showed that colloidal gold-conjugated MAbs 2A2 (CG-MAb) bond with JEV and the resulting complex was held by the other MAb 4D1 at the test line to give a reddish-purple band. Sensitivity tests demonstrated that ICS can detect 2.5 x 10(5) PFU of JEV.
The clinical screening results showed that the specificity and sensitivity of the ICS were 99.3% and 85.7% respectively as compared to that of RT-PCR. This suggests that the MAbs-based ICS test can be used as a convenient method for the rapid detection of JEV in infected swine samples. (C) 2010 Elsevier B.V. All rights reserved.”
“BACKGROUND
Clostridium difficile infection is a serious diarrheal illness associated with substantial morbidity and mortality. Patients generally have a response to oral vancomycin or metronidazole; selleck screening library however, the rate of recurrence is high. This phase 3 clinical trial compared the efficacy and safety of fidaxomicin with those of vancomycin in treating C. difficile infection.
METHODS
Adults with acute symptoms of C. difficile infection and a positive result on a stool toxin test were eligible for study entry. We randomly assigned patients to receive fidaxomicin (200 mg twice daily) or vancomycin (125 mg four times daily) orally for 10 days. The primary end point was clinical cure (resolution of symptoms and no need
for further therapy for C. difficile infection as of the second day after the end of the course of therapy). The secondary end points were FRAX597 clinical trial recurrence of C. difficile infection (diarrhea and a positive result on a stool toxin test within 4 weeks after treatment) and global cure (i.e.,
cure with no recurrence).
RESULTS
A total of 629 patients Oxygenase were enrolled, of whom 548 (87.1%) could be evaluated for the per-protocol analysis. The rates of clinical cure with fidaxomicin were noninferior to those with vancomycin in both the modified intention-to-treat analysis (88.2% with fidaxomicin and 85.8% with vancomycin) and the per-protocol analysis (92.1% and 89.8%, respectively). Significantly fewer patients in the fidaxomicin group than in the vancomycin group had a recurrence of the infection, in both the modified intention-to-treat analysis (15.4% vs. 25.3%, P = 0.005) and the per-protocol analysis (13.3% vs. 24.0%, P = 0.004). The lower rate of recurrence was seen in patients with non-North American Pulsed Field type 1 strains. The adverse-event profile was similar for the two therapies.
CONCLUSIONS
The rates of clinical cure after treatment with fidaxomicin were noninferior to those after treatment with vancomycin. Fidaxomicin was associated with a significantly lower rate of recurrence of C. difficile infection associated with non-North American Pulsed Field type 1 strains.